title: [Prostate-specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate].
abstract: Out of 62 patients with hormone-refractory metastatic prostate cancer, 34 received rescue treatment with estramustine phosphate and 28 received non-steroidal symptomatic treatment. All patients undergoing symptomatic treatment experienced increased PSA levels while in 16 (47%) patients treated with estramustine phosphate, PSA decreased between 13-96%. In 11 cases (32.3%) the decline in PSA was higher than 50%. In 5 (14.7%) the decline was lower than 50% and in 18 cases (53%) PSA levels were increased. SCR rate was 82%, 60% and 6% respectively while OCR were 36.4%., 0% and 0% respectively. No clinical response was seen in patients undergoing symptomatic treatment. A decline in PSA levels higher than 50% 12 weeks after treatment appears to be a "good prognosis" factor related to the best clinical response rates and survival.
authors.affiliation: Servicio de Urología, Hospital General Universitario Vall d'Hebron, Barcelona.
authors.forename: J
authors.initials: J
authors.lastname: Morote
authors.forename: J A
authors.initials: JA
authors.lastname: Lorente
authors.forename: C
authors.initials: C
authors.lastname: Vallejo
authors.forename: G
authors.initials: G
authors.lastname: Encabo
authors.forename: M A
authors.initials: MA
authors.lastname: López-Pacios
authors.forename: J A
authors.initials: JA
authors.lastname: De Torres
authors.forename: A
authors.initials: A
authors.lastname: Soler Rosello
mesh_terms: D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D004961:Estramustine; D017430:Prostate-Specific Antigen